8 completed, 5 terminated, 1 withdrawn. 6 Phase 2, 5 Phase 1, 3 Phase 3.
By phase and status
Follow Ophthotech Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Zimura, Eylea - Idiopathic Polypoidal Choroidal Vasculopathy Phase 2 Withdrawn 2018-11-01 2024-02-21 ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) Avacincaptad Pegol, Lucentis - Neovascular Age-related Macular Degeneration Phase 2 Completed 64 2017-10-11 2025-06-10 A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) Fovista®, bevacizumab, ranibizumab - Age-Related Macular Degeneration Phase 2 Terminated 63 2016-04-26 2024-10-30 A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Avacincaptad Pegol - Idiopathic Polypoidal Choroidal Vasculopathy Phase 2 Completed 4 2015-03-12 2025-03-20 Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD Fovista® (anti-PDGF BB) plus anti-VEGF - Age-related Macular Degeneration Phase 2 Terminated 101 2014-07-01 2024-02-23 A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy E10030, bevacizumab or aflibercept, E10030 sham injection - Age-Related Macular Degeneration Phase 3 Terminated 645 2014-05-01 2024-10-31 An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration Fovista™, Lucentis®, Avastin® - Neovascular Age-Related Macular Degeneration Phase 1 Completed 30 2014-02-01 2018-09-24 A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration Phase 3 Terminated 627 2013-08-01 2024-10-30 A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration Phase 3 Terminated 619 2013-08-01 2024-10-30 A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration E10030 plus Lucentis, Lucentis - Age-Related Macular Degeneration Phase 2 Completed 449 2010-03-01 2024-03-19 A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration Avacincaptad Pegol - Dry Age-Related Macular Degeneration Phase 1 Completed 47 2009-07-16 2025-03-10 ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration Avacincaptad Pegol - Neovascular Age-Related Macular Degeneration Phase 1 Completed 60 2008-10-16 2025-03-10 A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration volociximab - Age-related Macular Degeneration Phase 1 Completed 63 2008-10-01 2024-02-21 A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration E10030 - Age-related Macular Degeneration Phase 1 Completed 18 2007-12-01 2024-02-21
Conditions studied Macular Degeneration (8) · Choroidal Neovascularization (4) · Polypoidal Choroidal Vasculopathy (2)
Interventions Ranibizumab (7) · aflibercept (5) · Bevacizumab (4) · E10030 aptamer (4) · salicylhydroxamic acid (3) · volociximab (1)
Countries United States (13) · Hungary (3) · Latvia (3) · Argentina (2) · Australia (2) · Austria (2) · Brazil (2) · Canada (2) · Colombia (2) · Czechia (2) · Estonia (2) · France (2) · Germany (2) · Israel (2) · Italy (2)
Results publications PMID 30957581